CALR and essential thrombocythemia: This is in line with the observation of a prognostic unfavorable impact of the JAK2V617F mutation in pre-PMF versus a more benign course of disease in patients with a CALR mutation, which could not be seen in ET patients strictly diagnosed by WHO criteria15.